Show simple item record

Renal Cell Carcinoma

dc.contributor.authorLópez, José I.*
dc.date.accessioned2021-02-12T01:48:54Z
dc.date.available2021-02-12T01:48:54Z
dc.date.issued2020*
dc.date.submitted2020-06-09 16:38:57*
dc.identifier46036*
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/58186
dc.description.abstractRenal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.*
dc.languageEnglish*
dc.subjectQH301-705.5*
dc.subjectQ1-390*
dc.subject.classificationthema EDItEUR::P Mathematics and Science::PS Biology, life sciencesen_US
dc.subject.otherN-glycomapping*
dc.subject.othern/a*
dc.subject.otherSMAD proteins*
dc.subject.otherpatient survival*
dc.subject.otherpro-IL-1?*
dc.subject.othersurvival prediction*
dc.subject.otherinflammation markers*
dc.subject.othertumor migration*
dc.subject.otherprognostic factors*
dc.subject.otherpractical approach*
dc.subject.othercircular RNAs in a clinico-genomic predictive model*
dc.subject.otherglycomarkers*
dc.subject.otherreview*
dc.subject.othernephrectomy*
dc.subject.otheruric acid*
dc.subject.otherVEGF inhibitors*
dc.subject.othermetabolic reprogramming*
dc.subject.othercollecting duct carcinoma*
dc.subject.othercurcumin*
dc.subject.othermetabolome profiling*
dc.subject.otheridentification of circular RNAs*
dc.subject.otherIL-2*
dc.subject.otherexperimental validation of circular RNA*
dc.subject.otherRaf/MEK/ERK*
dc.subject.otherHOT*
dc.subject.otherPI3K/Akt/mTOR*
dc.subject.otherpentose phosphate pathway*
dc.subject.otherkidney cancer*
dc.subject.otherLOT*
dc.subject.othermutation*
dc.subject.otherRCC*
dc.subject.otherpolybromo-1*
dc.subject.otherpale cell*
dc.subject.otherMMP-9*
dc.subject.othergene expression*
dc.subject.otherrecurrence free survival*
dc.subject.otherchromosomal loss*
dc.subject.otherIL-1?*
dc.subject.otherchronic kidney disease*
dc.subject.otherglutathione transferase omega 2*
dc.subject.otherlabel-free*
dc.subject.otherglutathione transferase omega 1*
dc.subject.otheremerging entity*
dc.subject.othercopy number alteration*
dc.subject.otherFOXO3*
dc.subject.otherpredictive role*
dc.subject.othertumor slice culture*
dc.subject.othertyrosine kinase inhibitors*
dc.subject.otherPPP*
dc.subject.otherESC*
dc.subject.otherCDKN1A expression*
dc.subject.othermetastasis*
dc.subject.otherPD-L1*
dc.subject.otherdiagnostic and prognostic markers*
dc.subject.otherEVI1*
dc.subject.othercopy number loss*
dc.subject.otherRNA sequencing*
dc.subject.otherNK cells*
dc.subject.otherglutathione metabolism*
dc.subject.otherclear cell renal cell carcinoma*
dc.subject.otherrenal cell cancer*
dc.subject.otherproliferation*
dc.subject.othereosinophilic variant*
dc.subject.otherXp11 translocation renal cell carcinoma*
dc.subject.otherprognosis*
dc.subject.otherinvasion*
dc.subject.otherimmune infiltration*
dc.subject.otherIL4R?*
dc.subject.otherFISH*
dc.subject.other11) translocation renal cell carcinoma*
dc.subject.othertumor microenvironment*
dc.subject.othermetabolome*
dc.subject.otherhyperosmolality*
dc.subject.othertoxicity*
dc.subject.otherALK*
dc.subject.otherdrug sensitivity*
dc.subject.othert(6*
dc.subject.othercopy number analysis*
dc.subject.otherurine*
dc.subject.othergenetic association*
dc.subject.otherpolymorphism*
dc.subject.othersolute carrier proteins*
dc.subject.otherkidney*
dc.subject.othermetastatic ccRCC*
dc.subject.othermolecular genetic features*
dc.subject.otherrecurrence-free survival*
dc.subject.otherchromophobe renal cell carcinoma*
dc.subject.otherunclassified renal tumor*
dc.subject.otheroverall survival*
dc.subject.othermTOR inhibitors*
dc.subject.othermTOR*
dc.subject.otherJAK2*
dc.subject.othervon Hippel–Lindau*
dc.subject.othermiR-155-5p*
dc.subject.otherglycoproteomics*
dc.subject.otherPBRM1*
dc.subject.othermiR-133b*
dc.subject.othersurvival*
dc.subject.otherTFE3*
dc.subject.otherTFEB*
dc.subject.otheroncocytic renal tumor*
dc.subject.otherimmune checkpoint inhibitors*
dc.subject.otherbiomarker*
dc.subject.otherMMP10*
dc.subject.otherTCGA*
dc.subject.otherghrelin*
dc.subject.otherEMT like*
dc.subject.othercheckpoint inhibitors*
dc.subject.otherMiT family translocation renal cell carcinoma*
dc.subject.othergene signature*
dc.subject.othersarcomatoid*
dc.subject.othertransforming growth factor beta*
dc.subject.otherclear cell Renal Cell Carcinoma*
dc.subject.othertumor adhesion*
dc.subject.otherrenal cancer*
dc.subject.otherunclassified renal cell carcinoma*
dc.subject.otherPapillary renal cell carcinoma (pRCC)*
dc.subject.othermiR-146a-5p*
dc.subject.otherrenal cell*
dc.subject.othereverolimus*
dc.subject.otherintegrins*
dc.subject.othercytoreductive nephrectomy*
dc.subject.otherimmunotherapy*
dc.subject.otherpredictive factors*
dc.subject.otherimmunohistochemistry*
dc.subject.otherMTA2*
dc.subject.otherIL13R?1*
dc.subject.othertargeted therapy*
dc.subject.otherintratumour heterogeneity*
dc.subject.otheraurora A*
dc.subject.otherTCA cycle*
dc.subject.otherAMP-activated protein kinases*
dc.subject.othercancer-specific survival*
dc.subject.otherprogrammed death-ligand 1*
dc.subject.otherefficacy*
dc.subject.otherrenal cell carcinoma*
dc.subject.otheranaplastic lymphoma kinase rearrangement*
dc.subject.otherTFEB-amplified renal cell carcinoma*
dc.subject.otherstatins*
dc.subject.othercancer immunotherapy*
dc.subject.othermicroRNA*
dc.subject.othernew entity*
dc.subject.otherproteome profiling*
dc.titleRenal Cell Carcinoma*
dc.typebook
oapen.identifier.doi10.3390/books978-3-03928-639-3*
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0*
oapen.relation.isbn9783039286386*
oapen.relation.isbn9783039286393*
oapen.pages500*
oapen.edition1st*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/